Literature DB >> 29872562

Restricted T cell receptor repertoire in CLL-like monoclonal B cell lymphocytosis and early stage CLL.

Gonzalo Blanco1,2,3, Anna Vardi4, Anna Puiggros1,2, Andrea Gómez-Llonín1,2, Manuel Muro5, María Rodríguez-Rivera1,2, Evangelia Stalika4, Eugenia Abella6, Eva Gimeno6, Manuela López-Sánchez5, Alicia Senín6, Xavier Calvo1,2, Pau Abrisqueta7, Francesc Bosch7, Ana Ferrer1,2, Kostas Stamatopoulos4, Blanca Espinet1,2.   

Abstract

Analysis of the T cell receptor (TR) repertoire of chronic lymphocytic leukemia-like monoclonal B cell lymphocytosis (CLL-like MBL) and early stage CLL is relevant for understanding the dynamic interaction of expanded B cell clones with bystander T cells. Here we profiled the T cell receptor β chain (TRB) repertoire of the CD4+ and CD8+ T cell fractions from 16 CLL-like MBL and 13 untreated, Binet stage A/Rai stage 0 CLL patients using subcloning analysis followed by Sanger sequencing. The T cell subpopulations of both MBL and early stage CLL harbored restricted TRB gene repertoire, with CD4+ T cell clonal expansions whose frequency followed the numerical increase of clonal B cells. Longitudinal analysis in MBL cases revealed clonal persistence, alluding to persistent antigen stimulation. In addition, the identification of shared clonotypes among different MBL/early stage CLL cases pointed towards selection of the T cell clones by common antigenic elements. T cell clonotypes previously described in viral infections and immune disorders were also detected. Altogether, our findings evidence that antigen-mediated TR restriction occurs early in clonal evolution leading to CLL and may further increase together with B cell clonal expansion, possibly suggesting that the T cell selecting antigens are tumor-related.

Entities:  

Keywords:  T cell receptor (TR); antigen restriction; chronic lymphocytic leukemia (CLL); clonotype; monoclonal B cell lymphocytosis (MBL)

Year:  2018        PMID: 29872562      PMCID: PMC5980379          DOI: 10.1080/2162402X.2018.1432328

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  35 in total

1.  Oligoclonal TCRBV gene usage in B-cell chronic lymphocytic leukemia: major perturbations are preferentially seen within the CD4 T-cell subset.

Authors:  M R Rezvany; M Jeddi-Tehrani; A Osterborg; E Kimby; H Wigzell; H Mellstedt
Journal:  Blood       Date:  1999-08-01       Impact factor: 22.113

2.  TCRβ repertoire of CD4+ and CD8+ T cells is distinct in richness, distribution, and CDR3 amino acid composition.

Authors:  Hoi Ming Li; Toyoko Hiroi; Yongqing Zhang; Alvin Shi; Guobing Chen; Supriyo De; E Jeffrey Metter; William H Wood; Alexei Sharov; Joshua D Milner; Kevin G Becker; Ming Zhan; Nan-ping Weng
Journal:  J Leukoc Biol       Date:  2015-09-22       Impact factor: 4.962

3.  Age-dependent accumulation of monoclonal CD4+CD8+ double positive T lymphocytes in the peripheral blood of the elderly.

Authors:  Paolo Ghia; Giuseppina Prato; Stefania Stella; Cristina Scielzo; Massimo Geuna; Federico Caligaris-Cappio
Journal:  Br J Haematol       Date:  2007-12       Impact factor: 6.998

4.  A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies.

Authors:  Anna Lanemo Myhrinder; Eva Hellqvist; Ekaterina Sidorova; Anita Söderberg; Helen Baxendale; Charlotte Dahle; Kerstin Willander; Gerard Tobin; Eva Bäckman; Ola Söderberg; Richard Rosenquist; Sohvi Hörkkö; Anders Rosén
Journal:  Blood       Date:  2008-01-25       Impact factor: 22.113

5.  Monoclonal B cell lymphocytosis in hepatitis C virus infected individuals.

Authors:  Claudia Fazi; Antonis Dagklis; Francesca Cottini; Lydia Scarfò; Maria Teresa Sabrina Bertilaccio; Renato Finazzi; Massimo Memoli; Paolo Ghia
Journal:  Cytometry B Clin Cytom       Date:  2010       Impact factor: 3.058

6.  Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer.

Authors:  Alan G Ramsay; Andrew J Clear; Rewas Fatah; John G Gribben
Journal:  Blood       Date:  2012-04-30       Impact factor: 22.113

7.  Antigen Selection Shapes the T-cell Repertoire in Chronic Lymphocytic Leukemia.

Authors:  Anna Vardi; Andreas Agathangelidis; Evangelia Stalika; Maria Karypidou; Alexandra Siorenta; Achilles Anagnostopoulos; Richard Rosenquist; Anastasia Hadzidimitriou; Paolo Ghia; Lesley-Ann Sutton; Kostas Stamatopoulos
Journal:  Clin Cancer Res       Date:  2015-09-02       Impact factor: 12.531

8.  Production of autoantibodies by CD5-expressing B lymphocytes from patients with chronic lymphocytic leukemia.

Authors:  Z M Sthoeger; M Wakai; D B Tse; V P Vinciguerra; S L Allen; D R Budman; S M Lichtman; P Schulman; L R Weiselberg; N Chiorazzi
Journal:  J Exp Med       Date:  1989-01-01       Impact factor: 14.307

9.  Risk of developing chronic lymphocytic leukemia is influenced by HLA-A class I variation.

Authors:  M C Di Bernardo; P Broderick; S Harris; M J S Dyer; E Matutes; C Dearden; D Catovsky; R S Houlston
Journal:  Leukemia       Date:  2012-07-02       Impact factor: 11.528

10.  HLA specificities are associated with prognosis in IGHV-mutated CLL-like high-count monoclonal B cell lymphocytosis.

Authors:  María García-Álvarez; Miguel Alcoceba; Miriam López-Parra; Noemí Puig; Alicia Antón; Ana Balanzategui; Isabel Prieto-Conde; Cristina Jiménez; María E Sarasquete; M Carmen Chillón; María Laura Gutiérrez; Rocío Corral; José María Alonso; José Antonio Queizán; Julia Vidán; Emilia Pardal; María Jesús Peñarrubia; José M Bastida; Ramón García-Sanz; Luis Marín; Marcos González
Journal:  PLoS One       Date:  2017-03-01       Impact factor: 3.240

View more
  11 in total

1.  Control of chronic lymphocytic leukemia development by clonally-expanded CD8+ T-cells that undergo functional exhaustion in secondary lymphoid tissues.

Authors:  Bola S Hanna; Philipp M Roessner; Haniyeh Yazdanparast; Dolors Colomer; Elias Campo; Sabrina Kugler; Deyan Yosifov; Stephan Stilgenbauer; Manfred Schmidt; Richard Gabriel; Peter Lichter; Martina Seiffert
Journal:  Leukemia       Date:  2018-09-28       Impact factor: 11.528

2.  Select Antitumor Cytotoxic CD8+ T Clonotypes Expand in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib.

Authors:  Maria Joao Baptista; Sivasubramanian Baskar; Erika M Gaglione; Keyvan Keyvanfar; Inhye E Ahn; Adrian Wiestner; Clare Sun
Journal:  Clin Cancer Res       Date:  2021-04-19       Impact factor: 13.801

3.  Chronic lymphocytic leukemia-like monoclonal B-cell lymphocytosis exhibits an increased inflammatory signature that is reduced in early-stage chronic lymphocytic leukemia.

Authors:  Gonzalo Blanco; Anna Puiggros; Barbara Sherry; Lara Nonell; Xavier Calvo; Eulàlia Puigdecanet; Pui Yan Chiu; Yasmine Kieso; Gerardo Ferrer; Florencia Palacios; Magdalena Arnal; María Rodríguez-Rivera; Eva Gimeno; Eugènia Abella; Kanti R Rai; Pau Abrisqueta; Francesc Bosch; Alexandre Calon; Ana Ferrer; Nicholas Chiorazzi; Blanca Espinet
Journal:  Exp Hematol       Date:  2021-01-07       Impact factor: 3.249

Review 4.  Engaging Cytotoxic T and NK Cells for Immunotherapy in Chronic Lymphocytic Leukemia.

Authors:  Tom Hofland; Eric Eldering; Arnon P Kater; Sanne H Tonino
Journal:  Int J Mol Sci       Date:  2019-09-03       Impact factor: 5.923

5.  Ibrutinib Has Time-dependent On- and Off-target Effects on Plasma Biomarkers and Immune Cells in Chronic Lymphocytic Leukemia.

Authors:  Tom A Mulder; Lucía Peña-Pérez; Anna Berglöf; Stephan Meinke; H Yesid Estupiñán; Kia Heimersson; Rula Zain; Robert Månsson; C I Edvard Smith; Marzia Palma
Journal:  Hemasphere       Date:  2021-04-26

Review 6.  Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia.

Authors:  Valentina Griggio; Francesca Perutelli; Chiara Salvetti; Elia Boccellato; Mario Boccadoro; Candida Vitale; Marta Coscia
Journal:  Front Immunol       Date:  2020-11-18       Impact factor: 7.561

Review 7.  T-cells in chronic lymphocytic leukemia: Guardians or drivers of disease?

Authors:  Philipp M Roessner; Martina Seiffert
Journal:  Leukemia       Date:  2020-05-26       Impact factor: 11.528

Review 8.  Effects of ibrutinib on T-cell immunity in patients with chronic lymphocytic leukemia.

Authors:  Yanyan Liu; Yongping Song; Qingsong Yin
Journal:  Front Immunol       Date:  2022-08-19       Impact factor: 8.786

Review 9.  BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects.

Authors:  Marzia Palma; Tom A Mulder; Anders Österborg
Journal:  Front Immunol       Date:  2021-07-01       Impact factor: 7.561

Review 10.  Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL.

Authors:  Maissa Mhibik; Adrian Wiestner; Clare Sun
Journal:  Int J Mol Sci       Date:  2019-12-20       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.